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The recommended primary treatment approach for
women with metastatic breast cancer and an intact
primary tumor is the use of systemic therapy, with
local therapy for the primary tumor reserved for
palliation of symptoms. The past 6 years have seen an
accelerating pace of publication of studies examining
survival outcomes relative to the surgical resection of
the intact primary tumor in women with metastatic
breast cancer.
1–4 These show that in fact about half
the women presenting with de novo metastatic dis-
ease undergo resection of the primary tumor and
suggest that women so treated survive longer than
those treated without resection. In analyses that ad-
just for tumor burden (number of metastatic sites),
types of metastases (visceral, nonvisceral), and the
use of systemic therapy, the hazard of death is re-
duced by 40–50% in women receiving surgical treat-
ment of the primary tumor. Thus, five retrospective
studies including the report by Fields et al.
5 in the
present issue of the Annals of Surgical Oncology,
present us with consistent evidence that either surgi-
cal therapy of the primary tumor has a substantial
survival beneﬁt in women with metastatic breast
cancer, or there is a strong and consistent selection
bias driving the use of surgery in women who have
more favorable proﬁles (i.e., younger age, smaller
tumor burden, better access to care). It is also pos-
sible that surgery is a surrogate indicator of more
aggressive therapy overall, including more aggressive
systemic therapy, which translates into better sur-
vival. All authors acknowledge the problem of
selection bias in the interpretation of these data, and
all advocate for a randomized trial to settle this
question.
In this setting, what can we learn from additional
single-institution retrospective series addressing this
question? Single-institution studies are necessarily
smaller than the large data sets that are available
from the National Cancer Database (NCDB)
1 and
the Surveillance, Epidemiology, and End-Results
(SEER) program,
4 but provide richer detail regarding
the speciﬁcs of local and systemic therapy and the
course of the local disease. Such detailed information
can garner data on trends and practices to guide the
design of a randomized trial. Local therapy questions
that require further deﬁnition include the timing of
surgery, the importance of free surgical margins, and
the beneﬁt of axillary clearance and radiotherapy.
Additionally, data from single-institution series may
generate hypotheses regarding subsets of patients
who are more likely to beneﬁt from local therapy.
The timing of surgery (early, after response to
systemic therapy or later, only if indicated for palli-
ation) has not been examined in any detail, although
large databases such as NCDB and SEER capture the
ﬁrst course of treatment most accurately, and there-
fore women reported as having had surgical therapy
would most likely have received this early in their
course. This issue is relevant to the hypothesis that
local therapy of the primary tumor is beneﬁcial for
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3285women with metastatic disease: If the tumor func-
tions as a source of new metastatic deposits, treating
it early in the course would logically have greater
beneﬁt.
Despite theburgeoning dataonsurgicalresection of
the primary tumor, information on the use of axillary
dissectioninthispopulationisscant.Sofar,ithasbeen
assumedthatwomenwithstageIVdiseasearelikelyto
die before axillary control becomes a problem. How-
ever if surgical extirpation of the primary tumor is
beneﬁcial, it seems implausible that therapy for ax-
illary disease would not add beneﬁt, and one previous
study suggests a trend toward a larger beneﬁt for wo-
men who had both negative surgical margins and ax-
illary dissection (HR 0.2, 95% CI 0.02–1.9).
2
Similarly, regional radiotherapy data are limited to
the study of Rapiti et al., who reported that local
radiation was used in women undergoing breast-
conserving surgery, and the lack of radiotherapy
increased the hazard of death independently.
2 The
inability to distinguish local radiation from radiation
to metastatic sites is a limitation of the data in the
NCDB,
1 and in the SEER
4 program. This is an area
where single-institution reviews could provide in-
sights that would inform both trial design and (in the
interim) patient care.
The published data are unanimous in identifying
smaller tumor size as a selection factor for surgical
therapy. It appears unlikely that the resection of T1–2
tumors is motivated by a need to palliate symptoms
and suggests that uncontrolled local disease is a feared
complicationamongbothphysiciansandpatients.Itis
reasonable to assume that complete resection is pro-
tective against uncontrolled chest wall disease, but
direct data are limited. A retrospective study of 111
women, presented in abstract form at the Society of
Surgical Oncology in 2007, suggests not only that
surgery is strongly protective against uncontrolled
chest wall disease, but also that a controlled chest wall
mediates the benefit of surgical resection.
6
Looking at the report from Fields et al. in this
context, we again ﬁnd conﬁrmation that surgical
resection of the primary tumor is currently performed
in about half the women presenting with stage IV
disease and is associated with an approximate halving
of the hazard of death during the follow-up period in
multivariate analyses.
5 As in previous studies, the use
of surgery is associated with smaller tumor size.
1,2,4
The surgical group in this study included patients
who underwent surgical therapy at any point in
their course, and in about half these women surgery
was undertaken to palliate symptoms. It would be
of great interest to know how frequently surgical
therapy for palliation was successful in maintaining a
disease-free chest wall (particularly if radiotherapy
was not used). Axillary evaluation was performed on
143 of 187 women (76%), but no further information
is presented, and it is unclear if and how these data
were included in the multivariate survival analysis.
There is no discussion of radiotherapy data.
Fields et al. ﬁnd that women with bone-only
metastases lived longer than those with metastases at
other sites, with an adjusted hazard ratio of 0.76 (95%
CI 0.58–0.98).
5 These results are consistent with the
known indolent course of osseous metastases. Thus,
women with bone-only disease may beneﬁt from
surgical resection of the primary because they have a
longer period of time during which they can develop
uncontrolled chest wall disease; but in the absence of
randomized data, we cannot conclude that these
women derive a greater survival beneﬁt from surgery.
Finally, Fields et al. have included a comorbidity
score (ACE-27) that categorizes comorbid conditions
as none, mild, moderate, and severe; they ﬁnd that
this score is not signiﬁcantly predictive of survival.
5
Earlier data from the same institution showed that
the ACE-27 had the greatest impact on survival when
the force of mortality of the malignant diagnosis was
small (e.g., early breast or prostate cancer) and least
when it was high (e.g., stage IV breast cancer)
7. Thus,
in a highly lethal disease such as stage IV breast
cancer, comorbidity does not seem to play a signiﬁ-
cant role in determining survival.
Despite these continued attempts to adjust for
additional parameters in analysis, the fact remains
that no study will fully account for the selection
biases that confound the interpretation of retrospec-
tive data; and that a consistent, reproducible bias will
show up in all analyses that are subject to that bias.
The question of whether or not local therapy matters
in stage IV disease is increasingly important, given
the documented prolongation in survival of women
with stage IV breast cancer,
8 and the anticipation
that survival for this group will continue to improve
with newer targeted systemic agents. In addition, this
question has wider implications than the speciﬁc
population of women who present with de novo
metastases. An analogous situation exists in women
with synchronous in-breast recurrence and distant
metastases, and ultimately the answer to this question
will have implications for women with oligometas-
tases that may be suitable for local therapy.
The design of a prospective study will need to ad-
dress the full gamut of local therapy for the primary
tumor: surgical resection with free margins, axillary
control, and radiotherapy. Even if one were to
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surgical extirpation of the primary tumor without the
expense and eﬀort of a randomized trial, axillary and
radiation therapy pose economic and personal bur-
dens that cannot be justiﬁed based on the available
data. A randomized trial is required.
Arguments against a randomized trial include
questions as to whether limited cooperative group
resources should be devoted to a small minority of
patients, whether randomization will be accepted by
patients and physicians, and whether systemic ther-
apy can be standardized suﬃciently in a heteroge-
neous patient population. However, given the
apparent large eﬀect of surgery, it appears unlikely
that speciﬁc systemic therapy regimens will have a
large enough impact on survival to obscure the eﬀects
of surgery. Randomization is less likely to be a bar-
rier for physicians and patients if axillary dissection
and radiotherapy are part of the question, since these
interventions are not widely used in this group of
patients at present. Preliminary sample size calcula-
tions based on a 10% improvement in 3-year survival
suggest that such a trial would require about 700
patients, and if adopted across cooperative groups,
could be completed in 4 years if 2% of eligible women
participated. A similar trial by Flanigan et al. took 6
years to complete, but provided invaluable data for
patients with advanced renal cell carcinoma.
9
We are faced with the possibility of changing the
paradigm that governs our concepts of the interplay
of a primary tumor and metastases and the treatment
strategies that result from these concepts. A ran-
domized trial, with incorporation of exciting correl-
ative science questions, has enormous potential
rewards for our patients.
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